Form 4: Zoetis Executive Roxanne Lagano Reports Stock Transactions
SEC Form 4 Filing
Executive Vice President Roxanne Lagano reports stock transactions involving Zoetis Inc. common stock and restricted stock units.
Summary
- Roxanne Lagano, an Executive Vice President at Zoetis Inc., filed a Form 4 detailing changes in beneficial ownership of the company's securities.
- The report includes the acquisition of 536 shares of common stock upon the vesting of restricted stock units (RSUs) on February 6, 2025.
- A disposition of 214 shares of common stock was reported on the same date to cover tax obligations at a price of $174.12 per share.
- Following these transactions, Lagano directly owns 15,122 shares of Zoetis Inc. common stock.
- She also indirectly owns 811.5728 shares through the Zoetis Inc. Savings Plan (401(k)) as of December 31, 2024.
- The report also details holdings of restricted stock units (RSUs) which will vest over the next few years.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing reflects routine stock transactions related to executive compensation. There is no indication of unusual activity or significant concern.
Positives
- The vesting of RSUs indicates that the executive is meeting the conditions of their equity grants, which is generally tied to performance and continued service.
Negatives
- The sale of shares to cover tax obligations, while common, slightly reduces the executive's direct stake in the company.
Future Outlook
The executive's future stock ownership will be affected by the vesting schedule of the remaining RSUs.
Industry Context
Tracking executive stock transactions provides insights into management's perspective on the company's performance and future prospects within the animal health industry.
Comparison to Industry Standards
- Executive compensation packages in the pharmaceutical and animal health industries often include stock options and restricted stock units to align management's interests with those of shareholders.
- Vesting schedules and the proportion of equity-based compensation are generally comparable to those of executives at companies like Elanco and Merck Animal Health.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they are part of standard executive compensation practices.
Key Dates
| Date | Description |
|---|---|
| 2022/02/08 | Date of grant for 1,404.2782 restricted stock units that vest on the third anniversary. |
| 2023/02/08 | Date of grant for 1,194.7696 restricted stock units that vest in three annual installments. |
| 2024/02/06 | Date of grant for 536.2096 restricted stock units that vest in three annual installments. |
| 2024/12/31 | Date for common stock equivalents held in the Zoetis Inc. Savings Plan, a 401(k) plan. |
| 2025/02/06 | Date of transaction: Acquisition of common stock upon vesting of RSUs and disposition of shares for tax obligations. |
| 2025/02/10 | Date of signature for the Form 4 filing. |
Keywords
Form 4, Zoetis, Lagano, Stock, RSU, Executive, Ownership, Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.